SAREPTA ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Sarepta Therapeutics, Inc. and Encourages Investors to Contact the Firm

Core Viewpoint - A class action lawsuit has been filed against Sarepta Therapeutics, Inc. for allegedly misleading investors regarding the safety and revenue outlook of its gene therapy ELEVIDYS, intended for treating Duchenne muscular dystrophy [1][3]. Company Overview - Sarepta Therapeutics is a biopharmaceutical company focused on developing gene therapies, specifically ELEVIDYS, for Duchenne muscular dystrophy [3]. Allegations - The lawsuit claims that Sarepta made materially false and misleading statements about ELEVIDYS, leading investors to believe it was a safe therapy with no hindrances to broader application approval [3]. - Specific allegations include: - ELEVIDYS posed significant safety risks to patients [3]. - Trial protocols failed to detect severe side effects [3]. - Adverse events would lead to halted recruitment and dosing in trials, attracting regulatory scrutiny [3]. - Positive statements made by the company lacked a reasonable basis [3]. Stock Price Impact - Following a safety update on March 18, 2025, Sarepta's stock price fell by $27.81 per share (27.44%) to close at $73.54 [4]. - On April 4, 2025, after disclosing regulatory requests, the stock price dropped by $4.18 per share (7.13%) to close at $54.43 [4]. - A second patient death reported on June 15, 2025, caused the stock to fall by $15.24 per share (42.12%) to close at $20.91 [4]. - The FDA's safety communication on June 24, 2025, led to a further decline of $1.52 per share (8.01%) to close at $17.46 [4].